InnoCare Pharma (9969.HK) Stock Price
InnoCare Pharma Price
Over the last 8 years InnoCare Pharma grew revenue by 257.1% annually, reaching 2.30 B CNY. For InnoCare Pharma, the net margin of 27.2% is up versus -6.2% a few years ago. The consensus 12-month price target for InnoCare Pharma is 19.38 CNY, about 93.4% above where the stock trades today. Of 18 analysts, 16 rate the stock a buy — an overall Buy consensus.
InnoCare Pharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
InnoCare Pharma business model & stock analysis
Frequently asked questions about InnoCare Pharma
The business model of InnoCare Pharma Ltd revolves around the development and commercialization of innovative and targeted therapies for patients with various types of cancer. By leveraging its scientific expertise and strong research capabilities, InnoCare Pharma focuses on discovering and advancing breakthrough drug candidates, aiming to address unmet medical needs and improve the lives of patients. Through strategic collaborations and partnerships, the company is committed to accelerating the development and global commercialization of its proprietary medications. InnoCare Pharma's business model allows it to bring novel, safe, and effective treatments to market, ultimately contributing to the advancement of oncology care.
InnoCare Pharma Ltd primarily operates in the pharmaceutical industry.
The main competitors of InnoCare Pharma Ltd in the market include international pharmaceutical companies such as AstraZeneca, Pfizer, Novartis, and Roche. These companies are renowned for their strong presence in the pharmaceutical industry and their extensive product portfolios. InnoCare Pharma Ltd, an innovative biopharmaceutical company, strives to differentiate itself by focusing on developing and commercializing novel medicines targeting cancer and autoimmune diseases. As a dynamic player in the market, InnoCare Pharma Ltd aims to carve out a niche through its unique pipeline and therapeutic advancements, while continually competing with established industry leaders.
InnoCare Pharma Ltd is a biopharmaceutical company founded in 2015 in Suzhou, China. The company focuses on the discovery, development, and commercialization of innovative and differentiated therapeutics for the treatment of cancer and autoimmune diseases. InnoCare Pharma Ltd has quickly established itself as a leading player in the biopharmaceutical industry. With a strong commitment to research and development, the company has built a diverse pipeline of potential drug candidates. InnoCare Pharma Ltd's dedication to improving patient outcomes and addressing unmet medical needs has propelled its growth and garnered recognition in the global healthcare community.
InnoCare Pharma Ltd has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2020, raising a substantial amount of funds to support its research and development initiatives. InnoCare Pharma Ltd also obtained regulatory approval for its leading drug candidate, ICP-192, for the treatment of various types of cancer. Furthermore, the company has entered into strategic partnerships and collaborations with renowned pharmaceutical companies, enabling it to expand its global reach and accelerate the development and commercialization of its pipeline products. These achievements demonstrate InnoCare Pharma Ltd's commitment to advancing innovative therapies and its potential for growth in the biopharmaceutical industry.
InnoCare Pharma Ltd is primarily present in China, with its headquarters located in Beijing. The company focuses on research, development, and commercialization of innovative drugs to address unmet medical needs. With a strong emphasis on precision medicine, InnoCare Pharma aims to provide effective treatments for patients in China and globally. As a leading biopharmaceutical company, InnoCare Pharma has expanded its reach to international markets, ensuring its presence in various countries and regions worldwide.
InnoCare Pharma Ltd represents a set of core values and a corporate philosophy that guides its operations. The company is committed to innovation, aiming to develop and deliver breakthrough therapeutics to patients in need. InnoCare Pharma values integrity and transparency, fostering strong relationships with stakeholders, including patients, healthcare professionals, and investors. The company prioritizes quality and excellence in all aspects of its business, ensuring the highest standard of research, development, and manufacturing processes. InnoCare Pharma also believes in collaboration and teamwork, working closely with partners to achieve its goals.
Analysts currently set an average price target of 21.55 CNY for the InnoCare Pharma stock (median: 19.38 CNY), implying +117.7 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the InnoCare Pharma stock: 16 recommend buying, 2 holding and 0 selling. For 2026, analysts expect InnoCare Pharma to generate revenue of 2.71 B CNY and earnings per share of 0.21 CNY.
Converted at the current exchange rate, the InnoCare Pharma share trades at 1.34 EUR (10.02 CNY).
The InnoCare Pharma share (9969.HK) is listed on 4 stock exchanges, including: Hongkong (HKEX) (9969.HK), Frankfurt (33C.F), München (33C.MU).
InnoCare Pharma Ltd is a Chinese biopharmaceutical company that specializes in researching and developing novel drugs. The company focuses on the treatment of oncological, inflammatory, and metabolic diseases. Its business model involves discovering new drug candidates, conducting clinical trials, and marketing pharmaceutical products. InnoCare Pharma Ltd has experience in collaborating with international partners and has built a wide network of scientists and research institutions to accelerate the development of innovative therapies. The company's main divisions are research and development, production, and distribution. The research and development segment involves searching for new drug candidates for various diseases and conducting clinical trials to evaluate their effectiveness and safety. The production department is responsible for manufacturing and selling drugs based on the research and development findings. InnoCare Pharma Ltd is dedicated to developing novel therapies for cancer, inflammation, and metabolic disorders. It produces these therapies in partnerships with selected pharmaceutical manufacturers and sells them in the Chinese market, working with chosen distribution partners to reach patients. The company's important product portfolio includes the Janus Kinase (JAK) inhibitor candidate, intended for treating inflammatory conditions such as rheumatoid arthritis. Currently, the JAK candidate is in Phase II of development. Another significant drug candidate from InnoCare Pharma Ltd is ICP-192, also known as an ATR inhibitor. This drug is intended for cancer treatment and is currently in Phase I of clinical development. InnoCare Pharma Ltd stands out from other Chinese pharmaceutical companies due to its innovative approach to drug development. The company collaborates closely with research institutions in the USA, Europe, and Asia to improve the efficacy and safety of its drugs. In summary, the business model of InnoCare Pharma Ltd is based on the development of new and innovative drugs. The company leverages partnerships and networking opportunities with other research groups to accelerate research and development processes. Manufacturing and selling the medications occur in collaboration with other companies in the pharmaceutical industry. The portfolio focuses on innovative therapies for cancer, inflammation, and metabolic disorders. The company's future prospects are promising as the demand for new and innovative drugs continues to rise in the Chinese market.
The expected revenue of InnoCare Pharma is 2.71 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of InnoCare Pharma is 364.61 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of InnoCare Pharma is currently 48.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the InnoCare Pharma stock.
The price-to-sales ratio (P/S) of InnoCare Pharma is currently 6.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the InnoCare Pharma stock.
The Eulerpool Quality Score for InnoCare Pharma is 5/10.
The ISIN of InnoCare Pharma is KYG4783B1032. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of InnoCare Pharma is A2PVC2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of InnoCare Pharma is 9969.HK. The ticker symbol is used to trade InnoCare Pharma shares on the stock exchange.
InnoCare Pharma stock
InnoCare Pharma Peer Group
InnoCare Pharma Ticker
InnoCare Pharma FIGI
All fundamentals and in-depth analysis of InnoCare Pharma
Our stock analysis for InnoCare Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InnoCare Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.